The application of pancreatic cancer organoids for novel drug discovery

References

• Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002–1014.
   PubMed Web of Science ®Google Scholar
• Sabari JK, Santini F, Bergagnini I, et al. Changing the therapeutic landscape in non-small cell lung cancers: the evolution of comprehensive molecular profiling improves access to therapy. Curr Oncol Rep. 2017;19(4). doi: 10.1007/s11912-017-0587-4
   PubMedGoogle Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States [Internet]. Cancer Res. 2014;74(11):2913–2921.
   PubMed Web of Science ®Google Scholar
• Rahib L, Wehner MR, Matrisian LM, et al. Estimated projection of US cancer incidence and death to 2040. JAMA Network Open. 2021;4(4):e214708–e214708.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus Gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• Korkeila EA. Advanced pancreatic cancer-how to choose an adequate treatment option. World J Gastroenterol. 2015;21(38):10709.
   PubMedGoogle Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA -mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–327.
   PubMed Web of Science ®Google Scholar
• Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer. N Engl J Med. 2022;388(1):33–43.
   PubMedGoogle Scholar
• Raghavan S, Winter PS, Navia AW, et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021;184(25):6119–6137.
   PubMedGoogle Scholar
• Grünwald BT, Devisme A, Andrieux G, et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021;184(22):5577–5592.e18
   PubMedGoogle Scholar
• Lee JW, Komar CA, Bengsch F, et al. Genetically engineered mouse models of pancreatic cancer: the KPC model (LSL-Kras G12D/+;LSL-Trp53 R172H/+;Pdx-1-Cre), its variants, and their application in immuno-oncology drug discovery. Curr Protoc Pharmacol. 2016;73(1). DOI:10.1002/cpph.2.
   PubMedGoogle Scholar
• Froeling FEM, Marshall JF, Kocher HM. Pancreatic cancer organotypic cultures. J Biotechnol. 2010;148(1):16–23.
   PubMedGoogle Scholar
• Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459(7244):262–265.
   PubMed Web of Science ®Google Scholar
• Driehuis E, Van Hoeck A, Moore K, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(52):26580–26590.
   PubMedGoogle Scholar
• Joshi R, Castro De Moura M, Piñeyro D, et al. The DNA methylation landscape of human cancer organoids available at the American type culture collection. Epigenetics. 2020;15(11):1167–1177.
   PubMed Web of Science ®Google Scholar
• Boj SF, Il HC, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160(1–2):324–338.
   PubMed Web of Science ®Google Scholar
• Schütte U, Bisht S, Brossart P, et al. Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research. Expert Opin Drug Discov. 2011;6(1):33–48.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim H, Lee SH, et al. Establishment of patient-derived pancreatic cancer organoids from endoscopic ultrasound-guided fine-needle aspiration biopsies. Gut Liver. 2022;16(4):625–636.
   PubMedGoogle Scholar
• Driehuis E, Gracanin A, Vries RGJ, et al. Establishment of pancreatic organoids from normal tissue and tumors. STAR Protoc. 2020;1(3):100192.
   PubMedGoogle Scholar
• Seino T, Kawasaki S, Shimokawa M, et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell. 2018;22(3):454–467
   PubMed Web of Science ®Google Scholar
• Tiriac H, Belleau P, Engle DD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Dis. 2018;8(9):1112–1129.
   Google Scholar
• Demyan L, Habowski AN, Plenker D, et al. Pancreatic cancer patient-derived organoids can predict response to neoadjuvant chemotherapy. Ann Surg. 2022;276(3):450–462.
   PubMedGoogle Scholar
• Grossman JE, Muthuswamy L, Huang L, et al. Organoid sensitivity correlates with therapeutic response in patients with pancreatic cancer. Clin Cancer Res. 2021;28(4):708–718.
   Google Scholar
• Huang L, Bockorny B, Paul I, et al. PDX-derived organoids model in vivo drug response and secrete biomarkers. JCI Insight. 2020;5(21). doi: 10.1172/jci.insight.135544
   Google Scholar
• Frappart PO, Walter K, Gout J, et al. Pancreatic cancer-derived organoids – a disease modeling tool to predict drug response. United Eur Gastroenterol J. 2020;8(5):594–606.
   PubMedGoogle Scholar
• Izumchenko E, Paz K, Ciznadija D, et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol. 2017;28:2595–2605.
   PubMed Web of Science ®Google Scholar
• Beutel AK, Schütte L, Scheible J, et al. A prospective feasibility trial to challenge patient–derived pancreatic cancer organoids in predicting treatment response. Cancers (Basel). 2021;13(11):2539.
   PubMedGoogle Scholar
• Farshadi EA, Chang J, Sampadi B, et al. Organoids derived from neoadjuvant FOLFIRINOX patients recapitulate therapy resistance in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2021;28:27.
   PubMedGoogle Scholar
• Hennig A, Baenke F, Klimova A, et al. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. J Pathol. 2022;257(5):607–619.
   PubMedGoogle Scholar
• Georgakopoulos N, Prior N, Angres B, et al. Long-term expansion, genomic stability and in vivo safety of adult human pancreas organoids. BMC Dev Biol. 2020;20:1–20. Available from https://bmcdevbiol.biomedcentral.com/articles/10.1186/s12861-020-0209-5.
   PubMedGoogle Scholar
• Krieger TG, Le Blanc S, Jabs J, et al. Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy. Nat Commun. 2021;12(1):12.
   PubMedGoogle Scholar
• Shukla HD, Dukic T, Roy S, et al. Pancreatic cancer derived 3D organoids as a clinical tool to evaluate the treatment response. Front Oncol. 2022;12. DOI:10.3389/fonc.2022.1072774.
   Google Scholar
• Naumann M, Czempiel T, Lößner AJ, et al. Combined systemic drug treatment with proton therapy: investigations on patient-derived organoids. Cancers (Basel). 2022;14(15):3781.
   PubMedGoogle Scholar
• Jenssen C, Dietrich CF. Endoscopic ultrasound-guided fine-needle aspiration biopsy and trucut biopsy in gastroenterology - An overview. Best Pract Res Clin Gastroenterol. 2009;23:743–759.
   PubMed Web of Science ®Google Scholar
• Berger AW, Schwerdel D, Reinacher-Schick A, et al. A blood-based multi marker assay supports the differential diagnosis of early-stage pancreatic cancer. Theranostics. 2019;9(5):1280–1287.
   PubMedGoogle Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–237.
   PubMed Web of Science ®Google Scholar
• Bonanno L, Dal Maso A, Pavan A, et al. Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? Br J Cancer. 2022;127(3):383–393.
   PubMedGoogle Scholar
• Wu YH, Hung YP, Chiu NC, et al. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. Eur J Cancer. 2022;166:208–218.
   PubMedGoogle Scholar
• Mak IWY, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114.
   PubMed Web of Science ®Google Scholar
• Boehnke K, Iversen PW, Schumacher D, et al. Assay establishment and validation of a high-throughput screening platform for three-dimensional patient-derived colon cancer organoid cultures. J Biomol Screen. 2016;21(9):931–941.
   PubMedGoogle Scholar
• Hou S, Tiriac H, Sridharan BP, et al. Advanced development of primary pancreatic organoid tumor models for high-throughput phenotypic drug screening. SLAS Discov. 2018;23(6):574–584.
   PubMed Web of Science ®Google Scholar
• Doffo J, Bamopoulos SA, Köse H, et al. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proc Natl Acad Sci U S A. 2022;119:e2105691119.
   PubMedGoogle Scholar
• Ferguson FM, Nabet B, Raghavan S, et al. Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020;16:635–643.
   PubMed Web of Science ®Google Scholar
• Hirt CK, Booij TH, Grob L, et al. Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapy. Cell Genomics. 2022;2(2):100095.
   PubMedGoogle Scholar
• Watanabe S, Yogo A, Otsubo T, et al. Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer. BMC Cancer. 2022;22(1):1–12.
   PubMedGoogle Scholar
• Raphael BJ, Hruban RH, Aguirre AJ, et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32:185–203.e13.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371–2381.
   PubMed Web of Science ®Google Scholar
• Ying H, Dey P, Yao W, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30(4):355–385.
   PubMed Web of Science ®Google Scholar
• Burns TF, Borghaei H, Ramalingam SS, et al. Targeting KRAS-mutant non-small-cell lung cancer: one mutation at a time, with a focus on KRAS G12C mutations. J Clin Oncol. 2020;39:38.
   PubMedGoogle Scholar
• Wang CX, Wang TT, Zhang KD, et al. Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma. Acta Pharmacol Sin. 2022;43:2696–2708.
   PubMedGoogle Scholar
• Kazi A, Chen L, Xiang S, et al. Global phosphoproteomics reveal CDK suppression as a vulnerability to KRas addiction in pancreatic cancer. Clin Cancer Res. 2021;28:27.
   PubMedGoogle Scholar
• Gout J, Perkhofer L, Morawe M, et al. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut. 2021;70(4):743–760.
   PubMedGoogle Scholar
• Duan Z, Chinn D, Tu MJ, et al. Novel synergistic combination of mitotic arrest and promotion of apoptosis for treatment of pancreatic adenocarcinoma. Transl Oncol. 2019;12:683–692.
   PubMedGoogle Scholar
• Gilles ME, Hao L, Huang L, et al. Personalized RNA medicine for pancreatic cancer. Clin Cancer Res. 2018;24:1734–1747.
   PubMed Web of Science ®Google Scholar
• Votanopoulos KI, Forsythe S, Sivakumar H, et al. Model of patient-specific immune-enhanced organoids for immunotherapy screening: feasibility study. Ann Surg Oncol. 2020;28:27.
   PubMedGoogle Scholar
• Chyuan IT, Chu CL, Hsu PN. Targeting the tumor microenvironment for improving therapeutic effectiveness in cancer immunotherapy: focusing on immune checkpoint inhibitors and combination therapies. Cancers (Basel). 2021;13(6):1188.
   PubMedGoogle Scholar
• Lutz ER, Kinkead H, Jaffee EM, et al. Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. Oncoimmunology. 2014;3(11):e962401.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–322.
   PubMed Web of Science ®Google Scholar
• Yuki K, Cheng N, Nakano M, et al. Organoid models of tumor immunology. Trends Immunol. 2020;41(8):652–664.
   PubMed Web of Science ®Google Scholar
• Grönholm M, Feodoroff M, Antignani G, et al. Patient-derived organoids for precision cancer immunotherapy. Cancer Res. 2021;81(12):3149–3155.
   PubMedGoogle Scholar
• Norton J, Foster D, Chinta M, et al. Pancreatic cancer associated fibroblasts (CAF): under-explored target for pancreatic cancer treatment. Cancers (Basel). 2020;12(5):1347.
   PubMedGoogle Scholar
• Li X, Gulati M, Larson AC, et al. Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert. Semin Cancer Biol. 2022;86:14–27.
   PubMedGoogle Scholar
• Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110:20212–20217.
   PubMed Web of Science ®Google Scholar
• De Jesus-Acosta A, Sugar EA, O’Dwyer PJ, et al. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Br J Cancer. 2020;122(4):498–505.
   PubMedGoogle Scholar
• Wang LCS, Lo A, Scholler J, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2:154–166.
   PubMed Web of Science ®Google Scholar
• Biffi G, Oni TE, Spielman B, et al. Il1-induced Jak/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9:282–301.
   PubMed Web of Science ®Google Scholar
• Li J, Byrne KT, Yan F, et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity. 2018;49(1):178–193.e7.
   PubMed Web of Science ®Google Scholar
• Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 Activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19:456–469.
   PubMed Web of Science ®Google Scholar
• Yang G, Shen W, Zhang Y, et al. Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. Oncotarget. 2017;8(24):38378.
   PubMedGoogle Scholar
• Meng Q, Xie S, Gray GK, et al. Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids. J Immunother Cancer. 2021;9.
   Google Scholar
• Hogenson TL, Xie H, Phillips WJ, et al. Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers. JCI Insight. 2022;7(22). doi: 10.1172/jci.insight.158060
   Google Scholar
• Huang L, Holtzinger A, Jagan I, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med. 2015;21(11):1364–1371.
   PubMed Web of Science ®Google Scholar
• Kang Y, Deng J, Ling J, et al. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. J Clin Invest. 2022;10.
   Google Scholar
• Matthews IJM, Schuster B, Kashaf SS, et al. OrganoID: a versatile deep learning platform for tracking and analysis of single-organoid dynamics. PLOS Comput Biol. 2022;18(11):e1010584.
   PubMedGoogle Scholar
• Desmoulin F, Gilard V, Malet-Martino M, et al. Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine. Drug Metab Dispos. 2002;30:1221–1229.
   PubMed Web of Science ®Google Scholar
• Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol. 2010;624:25–37.
   PubMedGoogle Scholar
• Lu J, Jiang F, Lu A, et al. Linkers having a crucial role in antibody–drug conjugates. Int J Mol Sci. 2016;17:561.
   PubMed Web of Science ®Google Scholar
• Casale F, Canaparo R, Serpe L, et al. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res. 2004;50:173–179.
   PubMed Web of Science ®Google Scholar
• Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 2002;20:3683–3690.
   PubMed Web of Science ®Google Scholar
• Haque MR, Wessel CR, Leary DD, et al. Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment. Microsyst Nanoeng. 2022;8:36.
   PubMedGoogle Scholar
• Lai BFL, Lu RXZ, Hu Y, et al. Recapitulating pancreatic tumor microenvironment through synergistic use of patient organoids and organ-on-a-chip vasculature. Adv Funct Mater. 2020;30:2000545.
   PubMedGoogle Scholar
• Lai BFL, Lu RXZ, Davenport Huyer L, et al. A well plate–based multiplexed platform for incorporation of organoids into an organ-on-a-chip system with a perfusable vasculature. Nat Protoc. 2021;16:2158–2189.
   PubMedGoogle Scholar
• Schuster B, Junkin M, Kashaf SS, et al. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat Commun. 2020;11(1):1–12.
   PubMedGoogle Scholar
• Kibbey MC. Maintenance of the EHS sarcoma and Matrigel preparation. J Tissue Cult Methods. 1994;16:227–230.
   Google Scholar
• Broguiere N, Isenmann L, Hirt C, et al. Growth of epithelial organoids in a defined hydrogel. Adv Mater. 2018;30:1801621.
   Web of Science ®Google Scholar
• Below CR, Kelly J, Brown A, et al. A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoids. Nat Mater. 2021;21(1):110–119.
   PubMedGoogle Scholar
• Xiao W, Pahlavanneshan M, Eun CY, et al. Matrix stiffness mediates pancreatic cancer chemoresistance through induction of exosome hypersecretion in a cancer associated fibroblasts-tumor organoid biomimetic model. Matrix Biol Plus. 2022;14:100111.
   PubMedGoogle Scholar
• Osuna de la Peña D, Smd T, Collin E, et al. Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology. Nat Commun. 2021;12:12.
   PubMedGoogle Scholar
• Li NT, Wu NC, Cao R, et al. An off-the-shelf multi-well scaffold-supported platform for tumour organoid-based tissues. Biomaterials. 2022;291:121883.
   PubMedGoogle Scholar
• Breunig M, Merkle J, Melzer MK, et al. Differentiation of human pluripotent stem cells into pancreatic duct-like organoids. STAR Protoc. 2021;2(4):100913.
   PubMedGoogle Scholar
• Breunig M, Merkle J, Wagner M, et al. Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cells. Cell Stem Cell. 2021;28(6):1105–1124.e19
   PubMedGoogle Scholar
• Hohwieler M, Illing A, Hermann PC, et al. Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling. Gut. 2017;66:473–486.
   PubMed Web of Science ®Google Scholar
• Huang L, Desai R, Conrad DN, et al. Commitment and oncogene-induced plasticity of human stem cell-derived pancreatic acinar and ductal organoids. Cell Stem Cell. 2021;28(6):1090–1104.
   PubMedGoogle Scholar
• Merkle J, Breunig M, Schmid M, et al. CDKN2A-mutated pancreatic ductal organoids from induced pluripotent stem cells to model a cancer predisposition syndrome. Cancers (Basel). 2021;13(20):5139.
   PubMedGoogle Scholar
• Wiedenmann S, Breunig M, Merkle J, et al. Single-cell-resolved differentiation of human induced pluripotent stem cells into pancreatic duct-like organoids on a microwell chip. Nat Biomed Eng. 2021;1–17. Available from https://www.nature.com/articles/s41551-021-00757-2
   Google Scholar
• Melzer MK, Breunig M, Arnold F, et al. Organoids at the PUB: the porcine urinary bladder serves as a pancreatic niche for advanced cancer modeling. Adv Healthc Mater. 2022;2102345. Available from https://onlinelibrary.wiley.com/doi/full/10.1002/adhm.202102345
   Google Scholar
• Melzer MK, Breunig M, Lopatta P, et al. Protocol to use de-epithelialized porcine urinary bladder as a tissue scaffold for propagation of pancreatic cells. STAR Protoc. 2022;3(4):101869.
   PubMedGoogle Scholar
• Go YH, Choi WH, Bae WJ, et al. Modeling pancreatic cancer with patient-derived organoids integrating cancer-associated fibroblasts. Cancers (Basel). 2022;14:2077.
   PubMedGoogle Scholar
• Schuth S, Le Blanc S, Krieger TG, et al. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. J Exp Clin Cancer Res. 2022;41:1–14. Available from https://jeccr.biomedcentral.com/articles/10.1186/s13046-022-02519-7.
   PubMedGoogle Scholar
• Il CJ, Rim JH, Jang SI, et al. The role of Jagged1 as a dynamic switch of cancer cell plasticity in PDAC assembloids. Theranostics. 2022;12:4431–4445.
   PubMedGoogle Scholar
• Koikawa K, Kibe S, Suizu F, et al. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. 2021;184:4753–4771.
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Ohuchida K, Mochida Y, et al. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. J Exp Clin Cancer Res. 2022;41:41.
   PubMedGoogle Scholar
• Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment. Cell. 2018;175:1972–1988.e16.
   PubMed Web of Science ®Google Scholar
• Maloney E, Clark C, Sivakumar H, et al. Immersion bioprinting of tumor organoids in multi-well plates for increasing chemotherapy screening throughput. Micromachines. 2020;11(2):208.
   PubMedGoogle Scholar
• Bengtsson A, Andersson R, Rahm J, et al. Organoid technology for personalized pancreatic cancer therapy. Cell Oncol. 2021;44(2):251–260.
   Google Scholar
• Langer EM, Allen-Petersen BL, King SM, et al. Modeling tumor phenotypes in vitro with three-dimensional bioprinting. Cell Rep. 2019;26(3):608–623.e6.
   PubMed Web of Science ®Google Scholar
• Hakobyan D, Médina C, Dusserre N, et al. Laser-assisted 3D bioprinting of exocrine pancreas spheroid models for cancer initiation study. Biofabrication. 2020;12. DOI:10.1088/1758-5090/ab7cb8.
   PubMedGoogle Scholar
• Zhou Z, Cong L, Cong X. Patient-derived organoids in precision medicine: drug screening, organoid-on-a-chip and living organoid biobank. Front Oncol. 2021;11. DOI:10.3389/fonc.2021.762184
   Google Scholar
• Method of the Year 2017: organoids. Nat Methods. 2018;15(1):1.
   Web of Science ®Google Scholar
• Qian Y, Gong Y, Fan Z, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020;13(1). DOI:10.1186/s13045-020-00958-3.
   Google Scholar
• Berger AW, Schwerdel D, Ettrich TJ, et al. Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. Oncotarget. 2018;9(2):2076–2085.
   PubMedGoogle Scholar
• Herpers B, Eppink B, James MI, et al. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nat Cancer. 2022;3(4):418–436.
   PubMedGoogle Scholar